Modulation of EZH2 expression in T cells improves efficacy of anti-CTLA-4 therapy
Open accessThe DOI matches its Crossref record; 21 of the 22 references it cites were found in a registry or an index.
Abstract
Enhancer of zeste homolog 2-mediated (EZH2-mediated) epigenetic regulation of T cell differentiation and Treg function has been described previously; however, the role of EZH2 in T cell-mediated antitumor immunity, especially in the context of immune checkpoint therapy, is not understood. Here, we showed that genetic depletion of EZH2 in Tregs (FoxP3creEZH2fl/fl mice) leads to robust antitumor immunity. In addition, pharmacological inhibition of EZH2 in human T cells using CPI-1205 elicited phenotypic and functional alterations of the Tregs and enhanced cytotoxic activity of Teffs. We observed that ipilimumab (anti-CTLA-4) increased EZH2 expression in peripheral T cells from treated patients. We hypothesized that inhibition of EZH2 expression in T cells would increase the effectiveness of anti-CTLA-4 therapy, which we tested in murine models. Collectively, our data demonstrated that modulating EZH2 expression in T cells can improve antitumor responses elicited by anti-CTLA-4 therapy, which provides a strong rationale for a combination trial of CPI-1205 plus ipilimumab.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The cited source says what the claim attributes to it.
In the citing paper
“It was demonstrated that ipilimumab induces the expression of EZH2, a key epigenetic enzyme that plays an important role in cellular plasticity (115-118).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [116]
In the citing paper
“The combination of EZH2 inhibition with anti-CTLA4 therapy led to improved survival in the preclinical studies (116).”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [116]
In the citing paper
“On the basis of these observations, a series of preclinical studies were designed that identified a potential role for EZH2 in driving adaptive resistance to anti-CTLA4 therapy.”
From The Next Decade of Immune Checkpoint Therapy (2021) · cites this paper as [116]
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Role of Histone H3 Lysine 27 Methylation in Polycomb-Group Silencing
Cao, R., Wang, L., Wang, H., Xia, L., Erdjument-Bromage, H., Tempst, P., Jones, R. S., & Zhang, Y. (2002) · Science · doi:10.1126/science.1076997 · Cited by 3,775 · cited 1×
“EZH2 is a catalytic subunit of polycomb repressive complex 2 (PRC2) that trimethylates lysine 27 on histone H3 (H3K27me3), leading to gene repression (2, 3).”
BackgroundThe Polycomb complex PRC2 and its mark in life
Margueron, R., & Reinberg, D. (2011) · Nature · doi:10.1038/nature09784 · Cited by 3,347 · cited 1×
“EZH2 is a catalytic subunit of polycomb repressive complex 2 (PRC2) that trimethylates lysine 27 on histone H3 (H3K27me3), leading to gene repression (2, 3).”
BackgroundZhou, X., Bailey-Bucktrout, S. L., Jeker, L. T., Penaranda, C., Martínez-Llordella, M., Ashby, M., Nakayama, M., Rosenthal, W., & Bluestone, J. A. (2009) · Nature Immunology · doi:10.1038/ni.1774 · Cited by 1,370 · cited 1×
“CPI-1205–treated Tregs seem to acquire the phenotype of so-called exFoxP3 cells, which were previously shown to have an activated memory phenotype (19).”
BackgroundEpigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Peng, D., Kryczek, I., Nagarsheth, N., Zhao, L., Wei, S., Wang, W., Sun, Y., Zhao, E., Vatan, L., Szeliga, W., et al. (2015) · Nature · doi:10.1038/nature15520 · Cited by 1,201 · cited 1×
“As EZH2 regulates expression of Th-1 chemokines such as CXCL9 and CXCL10 in the tumor cells (14), we performed in vitro (cell line) and in vivo (murine tumor model) experiments to assess the contribution of CXCL9 and CXCL10 in our system.”
MethodWei, G., Wei, L., Zhu, J., Zang, C., Hu-Li, J., Yao, Z., Cui, K., Kanno, Y., Roh, T.-Y., Watford, W. T., et al. (2009) · Immunity · doi:10.1016/j.immuni.2008.12.009 · Cited by 1,152
Interferon-γ Drives Treg Fragility to Promote Anti-tumor Immunity
Overacre-Delgoffe, A. E., Chikina, M., Dadey, R. E., Yano, H., Brunazzi, E. A., Shayan, G., Horne, W., Moskovitz, J. M., Kolls, J. K., Sander, C., et al. (2017) · Cell · doi:10.1016/j.cell.2017.05.005 · Cited by 627
Stability and function of regulatory T cells is maintained by a neuropilin-1–semaphorin-4a axis
Delgoffe, G. M., Woo, S.-R., Turnis, M. E., Gravano, D. M., Guy, C., Overacre, A. E., Bettini, M. L., Vogel, P., Finkelstein, D., Bonnevier, J., et al. (2013) · Nature · doi:10.1038/nature12428 · Cited by 587
BACH2 represses effector programs to stabilize Treg-mediated immune homeostasis
Roychoudhuri, R., Hirahara, K., Mousavi, K., Clever, D., Klebanoff, C. A., Bonelli, M., Sciumè, G., Zare, H., Vahedi, G., Dema, B., et al. (2013) · Nature · doi:10.1038/nature12199 · Cited by 407
Kanno, Y., Vahedi, G., Hirahara, K., Singleton, K., & O'Shea, J. J. (2012) · Annual Review of Immunology · doi:10.1146/annurev-immunol-020711-075058 · Cited by 342
DuPage, M., Chopra, G., Quiros, J., Rosenthal, W. L., Morar, M. M., Holohan, D., Zhang, R., Turka, L., Marson, A., & Bluestone, J. A. (2015) · Immunity · doi:10.1016/j.immuni.2015.01.007 · Cited by 332 · cited 2×
“org Volume 128 Number 9 September 2018 Introduction Enhancer of zeste homolog 2 (EZH2) is expressed in T cells following its activation via CD28 signaling (1).”
Background
Cited by
Immune checkpoint therapy—current perspectives and future directions
Sharma, P., Goswami, S., Raychaudhuri, D., Siddiqui, B. A., Singh, P., Nagarajan, A., Liu, J., Subudhi, S. K., Poon, C., Gant, K. L., et al. (2023) · Cell · doi:10.1016/j.cell.2023.03.006 · Cited by 1,206
Self-citationEZH2: a novel target for cancer treatment
Duan, R., Du, W., & Guo, W. (2020) · Journal of Hematology & Oncology · doi:10.1186/s13045-020-00937-8 · Cited by 926
Li, C., Jiang, P., Wei, S., Xu, X., & Wang, J. (2020) · Molecular Cancer · doi:10.1186/s12943-020-01234-1 · Cited by 921
“Pharmacological modulating EZH2 expression in T cells can improve antitumor responses elicited by anti-CTLA-4 therapy [179].”
BackgroundThe Next Decade of Immune Checkpoint Therapy
Sharma, P., Siddiqui, B. A., Anandhan, S., Yadav, S. S., Subudhi, S. K., Gao, J., Goswami, S., & Allison, J. P. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-1680 · Cited by 750
Self-citationBurr, M. L., Sparbier, C. E., Chan, K. L., Chan, Y.-C., Kersbergen, A., Lam, E. Y. N., Azidis-Yates, E., Vassiliadis, D., Bell, C. C., Gilan, O., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.08.008 · Cited by 649
“, 2016), and targeted EZH2 disruption in regulatory T cells has been shown to enhance anti-tumor immune responses in mouse tumor models (Wang et al., 2018; Goswami et al., 2018).”
BackgroundTargeting the epigenetic regulation of antitumour immunity
Hogg, S. J., Beavis, P. A., Dawson, M. A., & Johnstone, R. W. (2020) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-0077-5 · Cited by 630
The roles of DNA, RNA and histone methylation in ageing and cancer
Michalak, E. M., Burr, M. L., Bannister, A. J., & Dawson, M. A. (2019) · Nature Reviews Molecular Cell Biology · doi:10.1038/s41580-019-0143-1 · Cited by 549
Combining epigenetic drugs with other therapies for solid tumours — past lessons and future promise
Morel, D., Jeffery, D., Aspeslagh, S., Almouzni, G., & Postel-Vinay, S. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0267-4 · Cited by 445
The emerging role of epigenetic therapeutics in immuno-oncology
Topper, M. J., Vaz, M., Marrone, K. A., Brahmer, J. R., & Baylin, S. B. (2020) · Nature Reviews Clinical Oncology · doi:10.1038/s41571-019-0266-5 · Cited by 433
Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer
Mohammad, H. P., Barbash, O., & Creasy, C. L. (2019) · Nature Medicine · doi:10.1038/s41591-019-0376-8 · Cited by 413
Epigenetic regulation in the tumor microenvironment: molecular mechanisms and therapeutic targets
Yang, J., Xu, J., Wang, W., Zhang, B., Yu, X., & Shi, S. (2023) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-023-01480-x · Cited by 388
Cancer Epigenetics, Tumor Immunity, and Immunotherapy
Cao, J., & Yan, Q. (2020) · Trends in Cancer · doi:10.1016/j.trecan.2020.02.003 · Cited by 346
Epigenetic modulation of antitumor immunity for improved cancer immunotherapy
Dai, E., Zhu, Z., Wahed, S., Qu, Z., Storkus, W. J., & Guo, Z. S. (2021) · Molecular Cancer · doi:10.1186/s12943-021-01464-x · Cited by 328
“Moreover, anti-CTLA-4 abs increased EZH2 expression in peripheral T cells isolated from treated patients [120].”
BackgroundRegulatory T cell control of systemic immunity and immunotherapy response in liver metastasis
Lee, J. C., Mehdizadeh, S., Smith, J., Young, A., Mufazalov, I. A., Mowery, C. T., Daud, A., & Bluestone, J. A. (2020) · Science Immunology · doi:10.1126/sciimmunol.aba0759 · Cited by 308
Zhou, L., Mudianto, T., Ma, X., Riley, R., & Uppaluri, R. (2020) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1351 · Cited by 269
“In regulatory T cells (Tregs), disruption of EZH2 can enhance antitumor immunity by diminishing the suppressive activity of Tregs and enhancing T-cell infiltration in the tumor (22, 23).”
BackgroundKundu, M., Butti, R., Panda, V. K., Malhotra, D., Das, S., Mitra, T., Kapse, P., Gosavi, S. W., & Kundu, G. C. (2024) · Molecular Cancer · doi:10.1186/s12943-024-01990-4 · Cited by 250
“They have shown that combination treatment might boost the therapeutic efficacy of antibodies that target CTLA-4 and decline the number of immune-suppressive cells [249].”
BackgroundInfluentialMorel, K. L., Sheahan, A. V., Burkhart, D. L., Baca, S. C., Boufaied, N., Liu, Y., Qiu, X., Cañadas, I., Roehle, K., Heckler, M., et al. (2021) · Nature Cancer · doi:10.1038/s43018-021-00185-w · Cited by 250
EZH2-Targeted Therapies in Cancer: Hype or a Reality
Eich, M.-L., Athar, M., Ferguson, J. E., & Varambally, S. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-2147 · Cited by 242
“Specifically, mice with EZH2-deficient Tregs were more sensitive to anti–CTLA4 therapy than wild-type mice, and Rag1 / mice (lymphocyte deficient) did not respond to EZH2 inhibition (104).”
BackgroundEpigenetics and beyond: targeting writers of protein lysine methylation to treat disease
Bhat, K. P., Ümit Kaniskan, H., Jin, J., & Gozani, O. (2021) · Nature Reviews Drug Discovery · doi:10.1038/s41573-020-00108-x · Cited by 234
Intrinsic Immunogenicity of Small Cell Lung Carcinoma Revealed by Its Cellular Plasticity
Mahadevan, N. R., Knelson, E. H., Wolff, J. O., Vajdi, A., Saigí, M., Campisi, M., Hong, D., Thai, T. C., Piel, B., Han, S., et al. (2021) · Cancer Discovery · doi:10.1158/2159-8290.cd-20-0913 · Cited by 227
“Since EZH2 inhibition can also affect T cells in vivo (34), we sought to experimentally isolate our analysis of tumor-intrinsic immunogenicity by examining the effects of EZH2 inhibition on RPP cells ex vivo prior to implantation.”
BackgroundMyeloid cell-targeted therapies for solid tumours
Goswami, S., Anandhan, S., Raychaudhuri, D., & Sharma, P. (2023) · Nature Reviews Immunology · doi:10.1038/s41577-022-00737-w · Cited by 220
Cancer immunotherapy: it’s time to better predict patients’ response
Pilard, C., Ancion, M., Delvenne, P., Jerusalem, G., Hubert, P., & Herfs, M. (2021) · British Journal of Cancer · doi:10.1038/s41416-021-01413-x · Cited by 205
Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy
Emran, A. A., Chatterjee, A., Rodger, E. J., Tiffen, J. C., Gallagher, S. J., Eccles, M. R., & Hersey, P. (2019) · Trends in Immunology · doi:10.1016/j.it.2019.02.004 · Cited by 205
Modulating Treg stability to improve cancer immunotherapy
Kang, J. H., & Zappasodi, R. (2023) · Trends in Cancer · doi:10.1016/j.trecan.2023.07.015 · Cited by 182
Niu, Z., Jin, R., Zhang, Y., & Li, H. (2022) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-022-01200-x · Cited by 170
Regulatory T cells in homeostasis and disease: molecular mechanisms and therapeutic potential
Wang, L., Liang, Y., Zhao, C., Ma, P., Zeng, S., Ju, D., Zhao, M., Yu, M., & Shi, Y. (2025) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-025-02326-4 · Cited by 210
Mechanisms of Polycomb group protein function in cancer
Parreno, V., Martinez, A., & Cavalli, G. (2022) · Cell Research · doi:10.1038/s41422-021-00606-6 · Cited by 168
Small-molecule MMP2/MMP9 inhibitor SB-3CT modulates tumor immune surveillance by regulating PD-L1
Ye, Y., Kuang, X., Xie, Z., Liang, L., Zhang, Z., Zhang, Y., Ma, F., Gao, Q., Chang, R., Lee, H., et al. (2020) · Genome Medicine · doi:10.1186/s13073-020-00780-z · Cited by 171
“For example, a combination of CPI-1205, which pharmacologically inhibits EZH2, plus ipilimumab increases the effectiveness of anti-CTLA-4 therapy in a mouse model [5].”
Current trends in sensitizing immune checkpoint inhibitors for cancer treatment
Wei, J., Li, W., Zhang, P., Guo, F., & Liu, M. (2024) · Molecular Cancer · doi:10.1186/s12943-024-02179-5 · Cited by 160
EZH2 Inhibition in Ewing Sarcoma Upregulates GD2 Expression for Targeting with Gene-Modified T Cells
Kailayangiri, S., Altvater, B., Lesch, S., Balbach, S. T., Göttlich, C., Kühnemundt, J., Mikesch, J., Schelhaas, S., Jamitzky, S., Meltzer, J., et al. (2019) · Molecular Therapy · doi:10.1016/j.ymthe.2019.02.014 · Cited by 131
Regulatory T cell targeting in cancer: Emerging strategies in immunotherapy
Dees, S., Ganesan, R., Singh, S., & Grewal, I. S. (2021) · European Journal of Immunology · doi:10.1002/eji.202048992 · Cited by 115
EZH2 function in immune cell development
Nutt, S. L., Keenan, C. R., Chopin, M., & Allan, R. S. (2020) · Biological Chemistry · doi:10.1515/hsz-2019-0436 · Cited by 111
Rugo, H. S., Jacobs, I. A., Sharma, S., Scappaticci, F. A., Paul, T. A., Jensen-Pergakes, K., & Malouf, G. G. (2020) · Advances in Therapy · doi:10.1007/s12325-020-01379-x · Cited by 113
Alvisi, G., Termanini, A., Soldani, C., Portale, F., Carriero, R., Pilipow, K., Costa, G., Polidoro, M. A., Franceschini, B., Malenica, I., et al. (2022) · Journal of Hepatology · doi:10.1016/j.jhep.2022.05.043 · Cited by 121
Targeting EZH2 for cancer therapy: From current progress to novel strategies
Zeng, J., Zhang, J., Sun, Y. J., Wang, J., Ren, C., Banerjee, S., Ouyang, L., & Wang, Y. (2022) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2022.114419 · Cited by 114
Targeting CDK12 for Cancer Therapy: Function, Mechanism, and Drug Discovery
Liu, H., Liu, K., & Dong, Z. (2021) · Cancer Research · doi:10.1158/0008-5472.can-20-2245 · Cited by 105
Next-generation combination approaches for immune checkpoint therapy
Goswami, S., Pauken, K. E., Wang, L., & Sharma, P. (2024) · Nature Immunology · doi:10.1038/s41590-024-02015-4 · Cited by 127
“Preclinical mouse models indicated that upregulation of EZH2 acts as a T cell-intrinsic mechanism of adaptive resistance to ipilimumab 114 , which led to an investigator-initiated phase 1b/2 clinical trial that combined an EZH1/2 inhibitor (DS3201) with ipilimumab (CTLA-4i) in patients with…”
A New Trend in Cancer Treatment: The Combination of Epigenetics and Immunotherapy
Liu, Z., Ren, Y., Weng, S., Xu, H., Li, L., & Han, X. (2022) · Frontiers in Immunology · doi:10.3389/fimmu.2022.809761 · Cited by 100
Functional CRISPR dissection of gene networks controlling human regulatory T cell identity
Schumann, K., Raju, S. S., Lauber, M., Kolb, S., Shifrut, E., Cortez, J. T., Skartsis, N., Nguyen, V. Q., Woo, J. M., Roth, T. L., et al. (2020) · Nature Immunology · doi:10.1038/s41590-020-0784-4 · Cited by 88
Overcoming Immune Checkpoint Blockade Resistance via EZH2 Inhibition
Kim, H. J., Cantor, H., & Cosmopoulos, K. (2020) · Trends in Immunology · doi:10.1016/j.it.2020.08.010 · Cited by 92
Bugide, S., Gupta, R., Green, M. R., & Wajapeyee, N. (2021) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.2102718118 · Cited by 90
Hallmarks of sex bias in immuno-oncology: mechanisms and therapeutic implications
Xiao, T., Lee, J., Gauntner, T. D., Velegraki, M., Lathia, J. D., & Li, Z. (2024) · Nature reviews. Cancer · doi:10.1038/s41568-024-00680-z · Cited by 99
Akhmedov, M., Martinelli, A., Geiger, R., & Kwee, I. (2019) · NAR Genomics and Bioinformatics · doi:10.1093/nargab/lqz019 · Cited by 102
Zhang, Y., Wu, M., Lu, W.-C., Li, Y., Chang, C. J., & Yang, J. (2024) · Cell Metabolism · doi:10.1016/j.cmet.2023.12.003 · Cited by 94
Predictive biomarkers for immune checkpoint blockade and opportunities for combination therapies
Shen, H., Yang, E. S.-H., Conry, M., Fiveash, J. B., Contreras, C. M., Bonner, J. A., & Shi, L. Z. (2019) · Genes & Diseases · doi:10.1016/j.gendis.2019.06.006 · Cited by 84
“As such, genetic depletion of EZH2 in Treg led to robust antitumor immunity; pharmacological inhibition of EZH2 in human T cells elicited phenotypic and functional alterations of Treg cells and enhanced cytotoxic activity of Teff cells; and, more importantly, EZH2 inhibition worked in synergy with anti-CTLA-4 therapy…”
BackgroundGounder, M. M., Zhu, G. G., Roshal, L., Lis, E., Daigle, S. R., Blakemore, S. J., Michaud, N. R., Hameed, M., & Hollmann, T. J. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-18-3133 · Cited by 81
“Tazemetostatmay have induced lymphocyte infiltration of the PCD through reported effects of EZH2 disruption on reprogramming of tumor infiltrating Tregs to stimulate T-cell infiltration (11, 12, 17) or by upregulating chemokine and cytokine expression (15, 19).”
BackgroundEZH2 Inhibition: A Promising Strategy to Prevent Cancer Immune Editing
Kang, N., Eccleston, M., Clermont, P., Latarani, M., Male, D. K., Wang, Y. Z., & Crea, F. (2020) · Epigenomics · doi:10.2217/epi-2020-0186 · Cited by 83
Sun, S., Feng, Y., Xu, D., Zheng, H., & Li, M. (2022) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2022.188700 · Cited by 87
Li, C., Wang, Y., Gong, Y., Zhang, T., Huang, J., Tan, Z. W., & Xue, L. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01045-1 · Cited by 84
“Immunotherapy Anti-CTLA-4 – Bladder cancer [38]”
BackgroundTackling tumor microenvironment through epigenetic tools to improve cancer immunotherapy
Lodewijk, I., Nunes, S. P., Henrique, R., Jerónimo, C., Dueñas, M., & Paramio, J. M. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01046-0 · Cited by 78
“Various studies described an enhanced effector-T cell infiltration and cytotoxic activation in the TME upon EZH2 inhibition as well as functional alterations of the Treg population resulting in Treg-mediated pro-inflammatory activities [93, 103, 121, 122].”
BackgroundTreg programming and therapeutic reprogramming in cancer
Ayala, M. A. M., Li, Z., & DuPage, M. J. P. (2019) · Immunology · doi:10.1111/imm.13058 · Cited by 78
Zhang, T., Gong, Y., Meng, H., Li, C., & Xue, L. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-00862-0 · Cited by 82
Jin, M. L., & Jeong, K. W. (2023) · Experimental & Molecular Medicine · doi:10.1038/s12276-023-01014-z · Cited by 76
Regulation of antitumor immunity by inflammation-induced epigenetic alterations
Karin, M., & Shalapour, S. (2021) · Cellular and Molecular Immunology · doi:10.1038/s41423-021-00756-y · Cited by 72
EZH1/EZH2 inhibition enhances adoptive T cell immunotherapy against multiple cancer models
Porazzi, P., Nason, S., Yang, Z., Carturan, A., Ghilardi, G., Guruprasad, P., Patel, R. P., Tan, M. T., Padmanabhan, A. A., Lemoine, J., et al. (2025) · Cancer Cell · doi:10.1016/j.ccell.2025.01.013 · Cited by 80
Histone methylation antagonism drives tumor immune evasion in squamous cell carcinomas
Li, Y., Goldberg, E. M., Chen, X., Xu, X., McGuire, J. T., Leuzzi, G., Karagiannis, D., Tate, T., Farhangdoost, N., Horth, C., et al. (2022) · Molecular Cell · doi:10.1016/j.molcel.2022.09.007 · Cited by 69
Frontiers in cancer immunotherapy—a symposium report
Cable, J., Greenbaum, B. D., Pe’er, D., Bollard, C. M., Bruni, S., Griffin, M. E., Allison, J. P., Wu, C. J., Subudhi, S. K., Mardis, E. R., et al. (2020) · Annals of the New York Academy of Sciences · doi:10.1111/nyas.14526 · Cited by 67
Harnessing Antitumor CD4+ T Cells for Cancer Immunotherapy
Khelil, M. B., Godet, Y., Abdeljaoued, S., Borg, C., Adotévi, O., & Loyon, R. (2022) · Cancers · doi:10.3390/cancers14010260 · Cited by 68
“In addition, EZH2 inhibition potentiates cancer response to anti-CTLA-4 [236] and anti-PD1 [237] therapies.”
BackgroundLeveraging epigenetics to enhance the efficacy of immunotherapy
Licht, J. D., & Bennett, R. L. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01100-x · Cited by 57
“Targeted disruption of EZH2 in regulatory T cells enhances the antitumor immune response in mouse models [58, 59].”
BackgroundDong, H., Liu, S., Zhang, X., Chen, S., Kang, L., Chen, Y., Ma, S., Fu, X., Liu, Y., Zhang, H., et al. (2019) · Cancer Research · doi:10.1158/0008-5472.can-19-0428 · Cited by 55
Predictive biomarkers and potential drug combinations of epi-drugs in cancer therapy
Yang, T., Yang, Y., & Wang, Y. (2021) · Clinical Epigenetics · doi:10.1186/s13148-021-01098-2 · Cited by 60
“Thus, the combination of CPI-1205 and ipilimumab alleviates the side effects of ipilimumab monotherapy, providing a basis for the targeting of the combination therapy [41].”
BackgroundImmunotherapy for SMARCB1-Deficient Sarcomas: Current Evidence and Future Developments
Ngo, C., & Postel-Vinay, S. C. (2022) · Biomedicines · doi:10.3390/biomedicines10030650 · Cited by 57
Drugging histone methyltransferases in cancer
Richart, L., & Margueron, R. (2020) · Current Opinion in Chemical Biology · doi:10.1016/j.cbpa.2019.11.009 · Cited by 51
Epigenetic remodeling of the immune landscape in cancer: therapeutic hurdles and opportunities
Tien, F., Lu, H., Lin, S., & Tsai, H.-C. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-022-00893-0 · Cited by 55
“EZH2 increases anti-tumor immunity of CD8+ T cells while mediates the immunosuppressive function of Treg cells [53, 54].”
BackgroundRe-education of the Tumor Microenvironment With Targeted Therapies and Immunotherapies
Ngiow, S. F., & Young, A. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.01633 · Cited by 54
“EZH2 inhibition destabilizes Foxp3 expression and inhibits tumor growth in vivo (72, 73).”
BackgroundEZH2 as a Regulator of CD8+ T Cell Fate and Function
Stairiker, C. J., Thomas, G. D., & Salek‐Ardakani, S. (2020) · Frontiers in Immunology · doi:10.3389/fimmu.2020.593203 · Cited by 53
“Furthermore, the effect of EZH2 inhibition on destabilizing the regulatory T cell lineage is another primary consideration that was demonstrated to impact antitumor immunity (48, 55).”
BackgroundResultInfluentialHoffmann, F., Niebel, D., Aymans, P., Ferring‐Schmitt, S., Dietrich, D., & Landsberg, J. (2020) · Clinical Epigenetics · doi:10.1186/s13148-020-0818-7 · Cited by 51
Lysine methyltransferase inhibitors: where we are now
Feoli, A., Viviano, M., Cipriano, A., Milite, C., Castellano, S., & Sbardella, G. (2022) · RSC Chemical Biology · doi:10.1039/d1cb00196e · Cited by 54
The epigenetic hallmarks of immune cells in cancer
Yu, J. H., Xiao, C., Fan, T. T., Deng, Z., Wang, D., Cai, W., Li, J., Liao, T., Li, C., & He, J. (2025) · Molecular Cancer · doi:10.1186/s12943-025-02255-4 · Cited by 62
“Similarly, combining the EZH2 inhibitor CPI-1205 enhances ipilimumab efficacy in the mice model [347].”
Xu, Y., Li, P., Liu, Y., Xin, D., Lei, W., Liang, A., Han, W., & Qian, W. (2022) · 癌症:英文版 · doi:10.1002/cac2.12313 · Cited by 49
“Another study found that CPI-1205, a small-moleculeEZH2 inhibitor, can alter Tregs’ phenotype and functions to augment anticancer responses induced by CTLA4 blockade [74].”
BackgroundTargeting PRC2 for the treatment of cancer: an updated patent review (2016 - 2020)
Dockerill, M., Gregson, C. L., & O’Donovan, D. H. (2020) · Expert Opinion on Therapeutic Patents · doi:10.1080/13543776.2021.1841167 · Cited by 49
Molecular Determinants of Soft Tissue Sarcoma Immunity: Targets for Immune Intervention
Tazzari, M., Bergamaschi, L., Vita, A. D., Collini, P., Barisella, M., Bertolotti, A., Ibrahim, T., Pasquali, S., Castelli, C., & Vallacchi, V. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22147518 · Cited by 57
Liang, Y. J., Wang, L., Ma, P., Ju, D., Zhao, M., & Shi, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1308264 · Cited by 44
“Indeed, another study has reported that inactivating EZH2 can reverse resistance to anti-CTLA-4 and IL-2 immunotherapies and inhibit the growth of melanoma (114).”
BackgroundChomiak, A. A., Tiedemann, R. L., Liu, Y., Kong, X., Cui, Y., Wiseman, A. K., Thurlow, K. E., Cornett, E. M., Topper, M. J., Baylin, S. B., et al. (2024) · Science Advances · doi:10.1126/sciadv.adk4423 · Cited by 48
Epigenetic regulators combined with tumour immunotherapy: current status and perspectives
Zhang, H., Pang, Y., Yi, L., Wang, X., Wei, P., Wang, H., & Lin, S. (2025) · Clinical Epigenetics · doi:10.1186/s13148-025-01856-6 · Cited by 45
“This results in positive changes to the anti-tumour immune response [142, 162].”
Wang, X., Brea, L. T., & Yu, J. (2019) · PubMed · Cited by 45
Regulating the regulatory T cells as cell therapies in autoimmunity and cancer
Hosseinalizadeh, H., Rabiee, F., Eghbalifard, N., Rajabi, H., Klionsky, D. J., & Rezaee, A. (2023) · Frontiers in Medicine · doi:10.3389/fmed.2023.1244298 · Cited by 49
“Suppression of EZH2 in Tregs (using Foxp3-cre ezh2fl/fl mice) and employing CPI-1205 (a pharmacological inhibitor of EZH2) resulted in functional modifications in Tregs and improved cytotoxic activity of effector T cells (65).”
Uttam, S., Stern, A. M., Sevinsky, C. J., Furman, S. A., Pullara, F., Spagnolo, D. M., Nguyen, L., Gough, A., Ginty, F., Taylor, D. L., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-17083-x · Cited by 42
Foskolou, I. P., Barbieri, L., Vernet, A., Bargiela, D., Cunha, P. P., Veliça, P., Suh, E., Pietsch, S., Matulevičiūtė, R., Rundqvist, H., et al. (2020) · Blood Advances · doi:10.1182/bloodadvances.2020002309 · Cited by 39
Hyperprogression: A novel response pattern under immunotherapy
Han, X., Alu, A., Xiao, Y., Wei, Y., & Wei, X. (2020) · Clinical and Translational Medicine · doi:10.1002/ctm2.167 · Cited by 42
Epigenetic Reprogramming of CD4+ Helper T Cells as a Strategy to Improve Anticancer Immunotherapy
Renaude, E., Kroemer, M., Borg, C., Peixoto, P., Hervouet, É., Loyon, R., & Adotévi, O. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.669992 · Cited by 46
“These results were correlated with an increased infiltration of Th1 cells and cytotoxic effector T cells in the TME as well as a depletion of Treg cells (114).”
ResultHow metabolism bridles cytotoxic CD8+ T cells through epigenetic modifications
Acker, H. H. V., Ma, S., Scolaro, T., Kaech, S. M., & Mazzone, M. (2021) · Trends in Immunology · doi:10.1016/j.it.2021.03.006 · Cited by 41
“The combination with checkpoint blockade may result in synergistic effects [95,141] + Atezolimumab NCT02220842”
BackgroundEpigenetic regulation and therapeutic targets in the tumor microenvironment
Xie, Z., Zhou, Z., Yang, S., Zhang, S., & Shao, B. (2023) · Molecular Biomedicine · doi:10.1186/s43556-023-00126-2 · Cited by 42
Regulation of T cell differentiation and function by epigenetic modification enzymes
Liu, H., Li, P., Wei, Z., Zhang, C., Xia, M., Du, Q., Chen, Y., Liu, N., Li, H., & Yang, X. (2019) · Seminars in Immunopathology · doi:10.1007/s00281-019-00731-w · Cited by 40
Guo, B., Tan, X., & Cen, H. (2020) · PLoS ONE · doi:10.1371/journal.pone.0242191 · Cited by 43
“Previous studies have shown that the disruption of EZH2 in regulatory T cells (Tregs) can enhance anti-tumor immunity by diminishing the suppressive activity of Tregs and enhancing T cell infiltration in the tumor [12, 13].”
Sutopo, N. C., Kim, J. H., & Cho, J. Y. (2023) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2023.188865 · Cited by 41
HDAC inhibitors enhance the anti-tumor effect of immunotherapies in hepatocellular carcinoma
Shen, C., Li, M., Duan, Y., Jiang, X., Hou, X., Xue, F., Zhang, Y., & Luo, Y. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1170207 · Cited by 44
“In addition to inhibiting the expression of CXCL10, EZH2 has also been shown to inhibit the expression of PD-L1 and reduce the effect of anti-CTLA-4 therapy (163, 164).”
BackgroundZhou, Z., Xu, J., Liu, S., Lv, Y., Zhang, R., Zhou, X., Zhang, Y., Weng, S., Xu, H. W., Ba, Y., et al. (2024) · Biomarker Research · doi:10.1186/s40364-024-00630-9 · Cited by 40
“…in TI-Tregs, where EZH2 is activated in a CD28-dependent manner and associates with Foxp3 trimethylates lysine 27 on histone H3 (H3K27me3) secondary to deposit H3K27me3 in regions of the genome that are supposed to remain silent, thereby suppressing inflammatory transcriptional programs [83].”
BackgroundEpigenetic modulation of immunotherapy and implications in head and neck cancer
Zhou, L., Xu, N., Shibata, H., Saloura, V., & Uppaluri, R. (2021) · Cancer and Metastasis Reviews · doi:10.1007/s10555-020-09944-0 · Cited by 37
Guo, L., Cao, C., Goswami, S., Huang, X., Ma, L., Guo, Y., Yang, B., Li, T., Chi, Y., Zhang, X., et al. (2020) · Clinical Science · doi:10.1042/cs20191261 · Cited by 35
Huang, J., Zhang, J., Guo, Z., Li, C., Tan, Z. W., Wang, J., Yang, J., & Xue, L. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.741302 · Cited by 39
Singh, D., Khan, M. A., & Siddique, H. R. (2023) · Epigenomics · doi:10.2217/epi-2023-0142 · Cited by 36
Epigenetic Control of Cdkn2a.Arf Protects Tumor-Infiltrating Lymphocytes from Metabolic Exhaustion
Koss, B. S., Shields, B. D., Taylor, E. M., Storey, A. J., Byrum, S. D., Gies, A. J., Washam, C. L., Choudhury, S. R., Ahn, J. H., Uryu, H., et al. (2020) · Cancer Research · doi:10.1158/0008-5472.can-20-0524 · Cited by 37
“These studies are motivated by a recently realized toxicity to T regulatory cells and the ability of H3K27me3 to mediate Th1-type chemokine expression in tumor cells (20, 52).”
BackgroundLiao, Q., Yang, J., Ge, S., Chai, P., Fan, J., & Jia, R. (2022) · Journal of Pharmaceutical Analysis · doi:10.1016/j.jpha.2022.11.009 · Cited by 39
Immune escape of head and neck cancer mediated by the impaired MHC-I antigen presentation pathway
Luo, X., Qiu, Y., Fitzsimonds, Z. R., Wang, Q., Chen, Q., & Lei, Y. L. (2024) · Oncogene · doi:10.1038/s41388-023-02912-2 · Cited by 37
“Joint use of EZH2 inhibitors with anti-CTLA4 has contributed to improved tumor control in mouse melanoma models, which is also seen in the head and neck region [31].”
Immunotherapy in Extensive-Stage Small Cell Lung Cancer
Sayed, R. E., & Blais, N. (2021) · Current Oncology · doi:10.3390/curroncol28050347 · Cited by 34
“Epigenetic regulators responsible for immunologic plasticity such as TAP1 and STING in addition to EZH2 were associated with MHC-I downregulation [49].”
BackgroundLi, X., Tian, S., Shi, H., Ta, N., Ni, X., Bai, C., Zhu, Z., Chen, Y., Shi, D., Huang, H., et al. (2024) · Cancer Gene Therapy · doi:10.1038/s41417-024-00732-4 · Cited by 39
Peeters, J. G. C., Silveria, S. L., Özdemir, M., Ramachandran, S., & DuPage, M. J. P. (2024) · Cell Reports · doi:10.1016/j.celrep.2024.114724 · Cited by 30
Hou, Y., Žák, J., Shi, Y., Pratumchai, I., Dinner, B., Wang, W., Qin, K., Weber, E. W., Teijaro, J. R., & Wu, P. (2024) · Cancer Immunology Research · doi:10.1158/2326-6066.cir-24-0089 · Cited by 40
Polycomb Directed Cell Fate Decisions in Development and Cancer
German, B., & Ellis, L. (2022) · Epigenomes · doi:10.3390/epigenomes6030028 · Cited by 37
“showed that EZH2 inhibition modifies the function of regulatory T-cells, promoting an effector-like T-cell response, which leads to increased antitumor immunity [275].”
Background
Metadata
- Authors
- Goswami, S., Apostolou, I., Zhang, J., Skepner, J., Anandhan, S., Zhang, X., Xiong, L., Trojer, P., Aparicio, A., Subudhi, S. K., Allison, J. P., Zhao, H., & Sharma, P.
- Affiliations
- The University of Texas MD Anderson Cancer Center (US)
- Constellation Pharmaceuticals (United States) (US)
- Corresponding author
- Sharma, Padmanee
- ORCID
- Venue
- Journal of Clinical Investigation
- Published
- 2018-07-30
- Volume
- 128
- Issue
- 9
- Pages
- 3813-3818
- ISSN
- 0021-9738 (ISSN-L)
- 1558-8238
- PMC
- PMC6118570
- OpenAlex
- W2807710457
- Cited by
- 244
- References
- 22
- Citations by year
- 2026: 16 · 2025: 28 · 2024: 37 · 2023: 25 · 2022: 28 · 2021: 46 · 2020: 41 · 2019: 21 · 2018: 2
- FWCI
- 10.32
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- Journal of Clinical Investigation (publishedVersion)
- Europe PMC (PubMed Central) (publishedVersion)
- PubMed Central (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Parker Institute for Cancer Immunotherapy, National Institutes of Health (R01CA163793)
- Topics
- Health Sciences › Medicine › Oncology › Cancer Immunotherapy and Biomarkers
- Life Sciences › Immunology and Microbiology › Immunology › T-cell and B-cell Immunology
- Life Sciences › Immunology and Microbiology › Immunology › Immunotherapy and Immune Responses
- Keywords
- EZH2, epigenetic regulation, CTLA-4, ipilimumab, CTLA-4 blockade, regulatory T cells, Foxp3, EZH2 inhibition, antitumor immunity, T cell immunity, combination immunotherapy, tumor immunology
- MeSH terms
- Enhancer of Zeste Homolog 2 Protein, Antineoplastic Agents, Immunological, Ipilimumab, Animals, Enzyme Inhibitors, Humans, Indoles, Mice, Inbred C57BL, Mice, Transgenic, Neoplasms, Experimental, Piperidines, Cell Line, Tumor, T-Lymphocytes, Regulatory, Mice, CTLA-4 Antigen
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.